Regeneron Pharmaceuticals

The $100B market cap biotech with $13B revenue powered by Dupixent, the blockbuster eczema and asthma drug heading for $12B+ peak sales, which is 30% higher than the runner-up autoimmune therapy. Regeneron's antibody platform also produced world-class eye disease and cancer treatments, with Eylea generating $5.8B in sales.